Format

Send to

Choose Destination
Respir Med. 2015 Jul;109(7):803-12. doi: 10.1016/j.rmed.2015.02.006. Epub 2015 Feb 19.

MicroRNA as tools and therapeutics in lung cancer.

Author information

1
The Ohio State University Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA; Dept. Pulmonary, Allergy, Critical Care and Sleep Medicine, The Ohio State University, Columbus, OH 43210, USA. Electronic address: Jennifer.Fleming@osumc.edu.
2
The Ohio State University Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA; Dept. Pulmonary, Allergy, Critical Care and Sleep Medicine, The Ohio State University, Columbus, OH 43210, USA; The Ohio State University James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. Electronic address: Patrick.Nana-Sinkam@osumc.edu.

Abstract

Lung cancer is the number one cause of cancer related deaths. The lack of specific and accurate tools for early diagnosis and minimal targeted therapeutics both contribute to poor outcomes. The recent discovery of microRNAs (miRNAs) revealed a novel mechanism for post-transcriptional regulation in cancer and has created new opportunities for the development of diagnostics, prognostics and targeted therapeutics. In lung cancer, miRNA expression profiles distinguish histological subtypes, predict chemotherapeutic response and are associated with prognosis, metastasis and survival. Furthermore, miRNAs circulate in body fluids and hence may serve as important biomarkers for early diagnosis or stratify patients for personalized therapeutic strategies. Here, we provide an overview of the miRNAs implicated in lung cancer, with an emphasis on their clinical utility.

KEYWORDS:

Cancer; Lung; microRNA

PMID:
25910758
PMCID:
PMC4466089
DOI:
10.1016/j.rmed.2015.02.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center